Keyword: Aurobindo Pharma
Rising Pharmaceuticals pleads to price fixing, and a pilot-scale lyophilization facility is being made available for pilot projects.
Catalent has been picked to manufacture BeiGene's immuno-oncology drug.
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
In eyeing Novartis' deal to sell assets to Aurobindo, the Federal Trade Commission is reportedly delving into a lawsuit the generics maker faces.
India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.
FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.
What's taking Novartis' Sandoz and Aurobindo so long in their $1 billion U.S. generics oral solids and dermatology deal? FTC happened.
Aurobindo and Glenmark are cited by the FDA. Takeda inks IBD discovery pact with Prometheus. Ascletis recruits Novartis veteran as CSO.
India’s Aurobindo, which has been racking up FDA actions right and left, acknowledged Monday a recent agency inspection resulted in a Form 483.
Avanir pays $116 million in Neudexta kickback suits; China unveils results for a procurement scheme; Aurobindo founder faces insider trading fine.